Latest Earnings Results: Q2 '26
Estimated EPS
-$0.13
Reported EPS
-$0.25
Surprise
-87.12%
Estimated Rev
$65.44M
Reported Rev
$71.55M
Surprise
+9.35%
• Reported GAAP EPS of -$0.25 down -47.06% YoY • Reported revenue of $71.55M up 21.53% YoY • Adaptive Biotechnologies expects full year MRD revenue between $268 million and $278 million, while total company operating expenses, including cost of revenue, are forecast between $350 million and $355 million.
Bullish Takeaway
Adaptive Biotechnologies achieved 22% total revenue growth driven by a 33% increase in MRD revenue, while also strengthening the balance sheet through a $345 million convertible senior notes offering.
Bearish Takeaway
Adaptive Biotechnologies reported a widened net loss of $39.9 million, a 40% revenue decline in the Immune Medicine segment, and announced a strategic separation of its two primary business segments.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | -$0.10 | -- | -- | N/A |
Q2 '26 | -$0.13 | -$0.25 | -87.12% | MISSED |
Q1 '26 | -$0.16 | -$0.13 | 18.99% | BEAT |
Q4 '25 | -$0.19 | -$0.09 | 51.49% | BEAT |
Q3 '25 | -$0.15 | $0.06 | 140.93% | BEAT |
